Pathological Tau Antibodies for Selective Aggregate Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Alzheimer's disease (AD) and related tauopathies lack effective agents to prevent or treat the spread of pathological tau aggregates, which contribute significantly to cognitive decline and neuron death.
Innovation Solution
Development of monoclonal antibodies that selectively bind to pathological tau, inhibiting its cell-to-cell transmission and aggregation, and are administered to prevent or treat AD and tauopathies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat Alzheimer's Disease, then general symptom management is achieved, but the spread of pathological tau aggregates cannot be prevented or reversed
Solution Approach 1:
The patent applies local quality by designing antibodies with specific affinity characteristics that differentiate between pathological and non-pathological tau. The antibodies exhibit high affinity for aggregated pathological tau conformations while maintaining low affinity for native tau, creating a localized selective action that targets only the harmful aggregated forms without affecting normal tau function
Solution Approach 2:
The patent utilizes parameter changes by modifying antibody affinity parameters to achieve selective binding. The antibodies are engineered with specific affinity ranges (Kd values) that allow discrimination between pathological and non-pathological tau based on conformational differences, enabling selective targeting through controlled binding strength parameters
2Measurement precision
If antibodies with high affinity for tau are developed, then binding to tau aggregates is enhanced, but non-specific binding to non-pathological tau may occur
Solution Approach 1:
The patent applies local quality by designing antibodies with specific affinity characteristics that differentiate between pathological and non-pathological tau. The antibodies exhibit high affinity for aggregated pathological tau conformations while maintaining low affinity for native tau, creating a localized selective action that targets only the harmful aggregated forms without affecting normal tau function
Solution Approach 2:
The patent applies inversion by reversing the typical antibody design approach. Instead of designing antibodies to bind all tau forms and then attempting to reduce non-specific binding, the invention designs antibodies from the outset to specifically recognize pathological conformational epitopes that are absent in non-pathological tau, making selectivity the primary design criterion rather than a secondary optimization target
3Measurement precision
If monoclonal antibodies are designed to recognize conformational epitopes, then specificity for pathological tau is improved, but the complexity of antibody development increases
Solution Approach 1:
The patent applies preliminary action by pre-immunizing animals with aggregated tau proteins to generate antibodies that naturally recognize pathological conformational epitopes. This preliminary exposure step ensures that the resulting antibody repertoire is enriched for conformation-specific binders before screening and selection processes begin
Solution Approach 2:
The patent applies copying by using recombinant aggregated tau proteins as immunogens that replicate the conformational features of endogenous pathological tau aggregates. These copied aggregate structures serve as templates for generating antibodies that recognize authentic pathological epitopes without requiring direct isolation from patient brains
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The monoclonal antibodies effectively reduce tau pathology in animal models, minimizing intraneuronal aggregates and improving cognitive outcomes without affecting amyloid-beta plaque burden.
Implementation Method 1
monoclonal antibodies that selectively bind to pathological tau, inhibiting its spread by recognizing conformational epitopes
Data Source
AI summary
The present disclosure provides monoclonal antibodies that selectively bind to pathological tau over native tau. In certain aspects, the antibodies inhibit or minimize propagation of tau aggregates and/or reduce spread of pathological tau in vivo. In other aspects, the disclosure comprises a method of treating, ameliorating, and/or preventing a tauopathy in a subject, comprising administering any one of the antibodies of the disclosure to the subject. In yet other aspects, the disclosure comprises methods of detecting pathological tau using any one of the antibodies of the disclosure.